In CKD patients, angiotensin II is activated by muscle catabolism, and it is able to further increase proteolysis, reducing blood levels of insulin-like growth factor-1 (IGF-1) and activating the transforming growth factor-β (TGF-β) pathway, which leads to the loss of muscle mass [15]. Here, IGF1 is linked to chronic kidney disease.